Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
FOXO Technologies Inc. filings document the company’s healthcare operating subsidiaries, securities registrations, capital structure and governance actions. Current reports describe amendments to the certificate of incorporation, authorized-share increases, preferred-stock designations, Series E preferred stock transactions, shareholder written consents and Regulation FD updates tied to hospital and corporate operations.
The filing record also includes an S-1 registration statement, unregistered equity issuance disclosures, executive-officer transition reporting, an NT 10-K late-filing notice and formal disclosures on internal controls, financial reporting processes and SEC reporting obligations. These documents record FOXO’s public-company status, ownership and voting matters, financing arrangements, risk-related reporting and material corporate events.
FOXO Technologies Inc. states its Board and a Majority Shareholder approved a reverse stock split range of one-for-one thousand (1:1,000) to one-for-ten thousand (1:10,000), to be effected at the Board’s sole discretion prior to November 30, 2026. The action was authorized by written consent dated May 18, 2026 and will be completed by filing a Certificate of Amendment with the Delaware Secretary of State.
The Information Statement discloses 4,261,663,700 shares of Common Stock outstanding as of the Record Date and shows estimated post-split outstanding shares between 4,261,664 (1:1,000) and 426,166 (1:10,000). The filing explains the Board’s rationale is to increase per-share trading price for potential OTCQB quotation or an exchange listing, notes prior FINRA processing issues have been addressed, and describes fractional-share treatment (round up).
FOXO Technologies Inc. entered into a Strategic Technology License Agreement with founder Jon R. Sabes and LongevityFP Technologies, LLC. The deal grants LongevityFP Technologies an exclusive worldwide license to commercialize FOXO’s epigenetics intellectual property, including two issued U.S. patents, datasets, and machine learning models.
LongevityFP Technologies will pay FOXO a royalty equal to 3% of net revenues from the licensed technology, capped at $1.3 million, and receives a ten-year exclusive option to acquire majority ownership of FOXO Labs, Inc. Depending on the option structure, FOXO would retain a 40% equity interest in the resulting epigenetics enterprise. The agreement includes mutual releases and resolves prior matters between the parties.
FOXO Technologies Inc. reached a settlement with J.H. Darbie & Co. to resolve obligations under several prior agreements. The company will issue 400 shares of Series D Cumulative Convertible Redeemable Preferred Stock and pay $175,000 in seven monthly installments of $25,000 from May through December 2026. If FOXO misses payments, the unpaid balance may be converted into Class A common shares at 90% of the 20‑day volume‑weighted average price, capped by a 4.99% beneficial ownership limit. Separately, a majority stockholder controlled by the CEO, holding about 95.56% of voting rights as of May 18, 2026, approved a reverse stock split by written consent. The reverse split will become effective no earlier than 20 days after mailing a definitive Schedule 14C and remains subject to FINRA approval.
FOXO Technologies Inc. is informing stockholders that its Board and a majority shareholder approved a reverse stock split to amend the Certificate of Incorporation, allowing a split ratio in the range 1:1,000 to 1:10,000, with the Board to select the final ratio and effect the split, if at all, prior to November 30, 2026. The Board and the Majority Shareholder provided written consents on May 13, 2026 and May 18, 2026, respectively, and the Reverse Split will become effective upon filing a Certificate of Amendment with the Delaware Secretary of State. As of the record date the Company had 4,261,663,700 shares of Common Stock outstanding and estimates post-split outstanding shares would range from approximately 4,261,664 (1:1,000) to 426,166 (1:10,000). The filing explains FINRA interactions that prevented a prior split, recent exchanges of Series A Preferred Stock for notes, fractional-share treatment (rounded up), and that no dissenters’ appraisal rights will be provided.
FOXO Technologies Inc. entered into two Exchange Agreements with institutional investors to restructure its Series A Cumulative Convertible Redeemable Preferred Stock into senior unsecured non-convertible promissory notes. Investor 1 exchanged 2,467.98834 Series A shares with a stated value of $2,467,988.34 for an equal principal amount note, and Investor 2 exchanged 5,307.09694 Series A shares with a stated value of $5,307,096.94 for a matching principal amount note.
The exchanged preferred shares are cancelled, and the investors no longer hold instruments with conversion rights to FOXO equity. Each Senior Note is non-interest bearing, unsecured, and matures on the earlier of May 12, 2027 or the occurrence of an Event of Default, with an 18% per annum default interest rate. The company agrees not to incur indebtedness senior to these notes, repayment is to occur upon completion of a public offering or up-listing to a recognized stock exchange, and proceeds are earmarked for working capital purposes.
FOXO Technologies Inc. reports Q1 2026 results with net revenues of $5.17 million, up from $3.17 million a year earlier, mainly from its healthcare and life science services businesses. Despite higher revenue, FOXO recorded a net loss to common stockholders of $1.74 million.
The company ended March 31, 2026 with $65,896 in cash and a working capital deficit of $27.1 million, and it carries $8.61 million of current debt. Management discloses that these conditions and ongoing losses raise substantial doubt about FOXO’s ability to continue as a going concern absent additional financing and improved cash flow.
FOXO Technologies Inc. is amending its charter to increase its authorized capital to 25,020,000,000 shares. This will consist of 25,000,000,000 shares of Class A Common Stock and 20,000,000 shares of Preferred Stock, each with a par value of $0.0001 per share.
The Certificate of Amendment was authorized and approved by stockholders and adopted in accordance with Sections 212 and 242 of the Delaware General Corporation Law. It is scheduled to become effective upon filing with the Delaware Secretary of State on May 3, 2026.
FOXO Technologies Inc. files its annual report for the year ended December 31, 2025, describing a diversified business spanning rural hospitals, behavioral health, life science specimen sourcing, and epigenetic labs. The company has expanded via acquisitions of Myrtle Recovery Centers, Rennova Community Health and Vector BioSource, and now operates a 25-bed Critical Access Hospital and related behavioral health facilities in Tennessee.
FOXO reports substantial net losses, a working capital deficit and significant debt, and its auditors raise substantial doubt about its ability to continue as a going concern. The report details heavy reliance on equity financing, difficulty accessing a $5.0 million equity line, prior intangible asset impairments in the epigenetics division, and high regulatory exposure across healthcare, life science services and lab activities. Control of voting power by a preferred stockholder and challenges completing a further reverse stock split weigh on capital structure flexibility and liquidity.
The Board and the holder controlling a majority of votes approved an amendment to increase authorized Class A Common Stock from 10,000,000,000 to 25,000,000,000 shares. The approval was by unanimous board consent on March 20, 2026 and by written shareholder consent on March 27, 2026.
The Authorized Increase becomes effective when the Certificate of Amendment is filed with the Delaware Secretary of State after the 20-day mailing period required by Rule 14c-2(b). As of the Record Date the Company had 3,732,660,939 shares of Common Stock outstanding.
FOXO Technologies Inc. states that its Board and a majority holder approved an amendment to increase authorized Class A Common Stock from 10,000,000,000 to 25,000,000,000 shares. The Board adopted the proposal on March 20, 2026 and the majority holder consented on March 27, 2026. The amendment becomes effective upon filing the Certificate of Amendment with the Delaware Secretary of State after the required 20‑day mailing period. As of the Record Date the company reported 3,732,660,939 shares of Common Stock outstanding and aggregate voting power of 196,232,517,288 votes. The Information Statement notes potential uses of the additional shares for conversions, financings, equity incentives, strategic transactions, and other corporate purposes.